Tag: RAS GTPase family inhibitor

Home / RAS GTPase family inhibitor

Categories

Adagrasib gets accelerated approval for KRAS G12C-mutated NSCLC

Jan 2023: Adagrasib (Krazati, Mirati Therapeutics, Inc.), a RAS GTPase family inhibitor, was given accelerated approval by the Food and Drug Administration (FDA) for adult patients with KRAS G12C-muta...
ras-gtpase-family-inhibitor

Scan the code